I get asked about GLP-1 medicines more than almost anything else right now. Many women I work with are already taking one for weight or blood sugar. Some with Mast Cell Activation Syndrome (MCAS) have read that these medicines might calm mast cells, and want to know if that is real.
This article is not a recommendation, for or against. It is a look at what has been reported, how strong that evidence is, and what is still unknown, so you can have a better-informed conversation with your own doctor.
What are GLP-1 medicines?
GLP-1 is a hormone your gut releases after eating. It helps release insulin, slows how fast your stomach empties and signals fullness to the brain. GLP-1 receptor agonists, such as semaglutide, liraglutide and tirzepatide, are prescription medicines that copy this hormone. In Australia they are approved for type 2 diabetes and, for some, weight management. They are not approved for MCAS.
Why Anyone Thinks They Might Affect Mast Cells
GLP-1 receptors are not only in the gut and pancreas. They are found on many cell types, including immune cells, which is why researchers started asking whether these medicines do more than lower weight and blood sugar.
The early signals come from three directions:
- Animal studies. In mice, GLP-1 medicines reduced allergic-type airway inflammation, and in rats with obesity-related kidney disease, liraglutide reduced mast cell build-up in the kidney (Foer et al., 2023; He et al., 2017).
- Inflammatory skin conditions. Reviews describe improvements in psoriasis and other inflammatory skin diseases in people taking GLP-1 medicines (Persson et al., 2025).
- A large real-world study. In people with asthma and diabetes, adding a GLP-1 medicine was linked with about 40% fewer asthma attacks, and the effect did not seem to depend on weight loss (Lee et al., 2025).
None of this is MCAS research. It suggests these medicines may calm some kinds of inflammation, which is why clinicians who treat MCAS became curious.
Emerging A calming effect on inflammation is plausible, but it has mostly been shown in animals and in other conditions, not in people with MCAS.
What Has Been Reported in MCAS and Related Conditions
These are the published reports I found on PubMed (October 2026) that look at GLP-1 medicines in MCAS or closely related conditions:
| Report | Who | What happened | How strong |
|---|---|---|---|
| Afrin et al., 2025 | 47 people with MCAS that had not responded to other treatment (89% women) | 89% reported benefit across a range of symptoms | Case series, no comparison group |
| Kwiek et al., 2026 | 2 women (44 and 45) with long-standing chronic hives | Hives cleared within 3 weeks of starting a GLP-1 medicine for other reasons, still clear 6 months later | Two cases |
| Blitshteyn et al., 2026 | 1 woman with dysautonomia after vaccination | Fewer fainting-type symptoms and a lower heart rate on semaglutide | One case |
The largest report, 47 people, comes from clinicians who already believed the medicines might help, and there was no group taking a placebo. That does not make it wrong, but it means we cannot yet separate the medicine’s effect from hope, time or other changes. The authors themselves say randomised trials are needed.
In my own work, I hear from women who noticed changes in their flares after starting a GLP-1 medicine for another reason, in both directions. That is experience, not evidence, and it is exactly why proper trials matter.
Emerging Early reports are striking, but no controlled trial has tested GLP-1 medicines in MCAS. We do not know who benefits, at what dose, or for how long.
The Other Side: Side Effects and Cautions
The hopeful reports only tell half the story. These medicines have well-documented side effects, and some matter more if you have MCAS.
- Gut symptoms are the most common. Nausea, vomiting, diarrhoea and abdominal pain are frequent, especially early on and when the dose goes up (Long et al., 2024). In the large weight-loss trial of semaglutide, 4.5% stopped because of gut side effects (Wilding et al., 2021). Many people with MCAS already live with gut symptoms, so it can be hard to tell what is a flare and what is the medicine.
- Slower stomach emptying. This is part of how the medicines work, but it can worsen bloating, reflux and nausea.
- Allergic-type reactions can happen. Injection site reactions, rashes and, rarely, anaphylaxis have been reported (Long et al., 2024; Salazar et al., 2024). In the tirzepatide trials, most of these reactions were mild (Mullins et al., 2024). For someone whose mast cells react easily, this is worth discussing before starting.
- Other known risks include gallbladder problems, pancreatitis and low blood sugar when combined with some diabetes medicines (Long et al., 2024).
Only use medicines from an Australian pharmacy on a prescription. Since 1 October 2024, pharmacies in Australia can no longer make compounded “copies” of semaglutide or tirzepatide, because of safety and quality concerns (Australian Pharmacist). Products bought online without a prescription may not contain what they claim.
Established The common side effects above are well documented in large trials. How often people with MCAS react to these medicines has not been studied.
Why This Matters in Midlife
Many women start a GLP-1 medicine in their 40s and 50s. Three things are worth knowing at this stage of life.
Muscle goes too, not just fat. In a body-composition sub-study of a tirzepatide trial, about a quarter of the weight lost was lean mass, which includes muscle (Look et al., 2025). Muscle already declines with age and falling oestrogen. A review by an Australian team suggests resistance training alongside these medicines to help protect it (Locatelli et al., 2024). As a fitness coach, this is the part I would never skip: strength training and enough protein matter even more if your appetite drops.
HRT may change the response. In a small study of postmenopausal women on semaglutide, those using menopausal hormone therapy lost more weight at 12 months, 16% compared with 12% (Hurtado et al., 2024). The study was observational and the authors call for larger trials.
Perimenopause itself is barely studied. A 2025 review found very little data on how women in perimenopause respond to these medicines (Mikdachi & Dunsmoor-Su, 2025). No study I found has looked specifically at women with both MCAS and perimenopause.
Not yet studied How GLP-1 medicines interact with MCAS during the hormonal swings of perimenopause is unknown.
Questions to Take to Your Doctor
Whether you are already taking a GLP-1 medicine or wondering about one, these questions can make the conversation more useful:
- Given my MCAS, what reactions should I watch for, and what should I do if I react?
- How will we tell the difference between a side effect and one of my usual flares?
- If my gut symptoms get worse, what is the plan?
- How can I protect my muscle and bone while my appetite is lower?
- Does my HRT, or any other medicine I take, change anything?
- If you have read about GLP-1 medicines and MCAS: what does my doctor think of the early evidence, and is it relevant to me?
A symptom diary started a few weeks before any change gives you both a baseline to compare against.
Seek urgent care
Call 000 for swelling of the lips, tongue or throat, trouble breathing, severe tummy pain, or feeling faint with hives.
Important
This article is general information, not a recommendation to start, stop or change any medicine. GLP-1 medicines are prescription-only, and using them for MCAS is outside their approved use and untested in trials. Please make any decision with your own doctor.
Frequently Asked Questions
Can GLP-1 medicines help MCAS?
Some early reports suggest they might, including a case series of 47 people. There are no controlled trials yet, so we do not know who benefits or whether the effect is real. They are not approved for MCAS in Australia.
Can GLP-1 medicines cause allergic reactions?
Yes. Injection site reactions and rashes are reported, and anaphylaxis is rare. People with MCAS may want to discuss this risk with their doctor before starting.
I have MCAS and take a GLP-1 medicine for weight. Should I stop?
Do not stop or change a prescribed medicine on your own. Talk to your prescriber about any new or worsening symptoms.
Do GLP-1 medicines cause muscle loss?
Part of the weight lost is lean mass, which includes muscle. Resistance training and adequate protein can help protect it, which matters more in midlife.
Keep reading: MCAS and HRT: can you take it? and Progesterone and MCAS: calming for some, a trigger for others. Free guides on midlife nutrition, sleep and exercise are on the free resources page.
References
- Afrin LB, Weinstock LB, Dempsey TT, et al. Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome. American Journal of the Medical Sciences. 2025;370(4):377-382. doi:10.1016/j.amjms.2025.07.006
- Kwiek B, Sieczych J, Łukowska K, et al. Improvement of chronic spontaneous urticaria after glucagon-like peptide 1 receptor agonist therapy: report of two cases. Dermatology and Therapy. 2026;16(2):1419-1425. doi:10.1007/s13555-025-01640-7
- Blitshteyn S, Schofield JR, Haire N, et al. Improvement of post-COVID-19 vaccination dysautonomia with GLP-1 receptor agonist. Immunopharmacology and Immunotoxicology. 2026. doi:10.1080/08923973.2026.2731357
- Foer D, Amin T, Nagai J, et al. Glucagon-like peptide-1 receptor pathway attenuates platelet activation in aspirin-exacerbated respiratory disease. Journal of Immunology. 2023;211(12):1806-1813. doi:10.4049/jimmunol.2300102
- He J, Yuan G, Cheng F, et al. Mast cell and M1 macrophage infiltration and local pro-inflammatory factors were attenuated with incretin-based therapies in obesity-related glomerulopathy. Metabolic Syndrome and Related Disorders. 2017;15(7):344-353. doi:10.1089/met.2017.0057
- Persson C, Eaton A, Mayrovitz HN. A closer look at the dermatological profile of GLP-1 agonists. Diseases. 2025;13(5). doi:10.3390/diseases13050127
- Lee B, Man KKC, Wong E, et al. Antidiabetic medication and asthma attacks. JAMA Internal Medicine. 2025;185(1):16-25. doi:10.1001/jamainternmed.2024.5982
- Long B, Pelletier J, Koyfman A, et al. GLP-1 agonists: a review for emergency clinicians. American Journal of Emergency Medicine. 2024;78:89-94. doi:10.1016/j.ajem.2024.01.010
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Salazar CE, Patil MK, Aihie O, et al. Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature. Archives of Dermatological Research. 2024;316(6):248. doi:10.1007/s00403-024-02969-3
- Mullins GR, Hodsdon ME, Li YG, et al. Tirzepatide immunogenicity on pharmacokinetics, efficacy, and safety: analysis of data from phase 3 studies. Journal of Clinical Endocrinology & Metabolism. 2024;109(2):361-369. doi:10.1210/clinem/dgad532
- Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism. 2025;27(5):2720-2729. doi:10.1111/dom.16275
- Locatelli JC, Costa JG, Haynes A, et al. Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition? Diabetes Care. 2024;47(10):1718-1730. doi:10.2337/dci23-0100
- Hurtado MD, Tama E, Fansa S, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause. 2024;31(4):266-274. doi:10.1097/GME.0000000000002310
- Mikdachi H, Dunsmoor-Su R. GLP-1 receptor agonists for weight loss for perimenopausal and postmenopausal women: current evidence. Current Opinion in Obstetrics and Gynecology. 2025;37(2):97-101. doi:10.1097/GCO.0000000000001015
- Australian Pharmacist. News report on the ban of compounded GLP-1 medicines in Australia, 2024. australianpharmacist.com.au